CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for iNtRON Biotechnology Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

iNtRON Biotechnology Inc
701-704, 5th JungAng Induspia
138-6, Sangdaewon-Dong, Jungwon-Gu
Phone: +82 317395678p:+82 317395678 SEONGNAM, 13202  South Korea Ticker: 048530048530
Business Summary
iNtRON Biotechnology, Inc. is a Korea-based company principally engaged in the biotechnology industry. The Company operates its business through two main divisions: genetic reagent division and molecular diagnostics division. Its genetic reagent division is involved in the research and development of reagents, which are under the brand names of Maxime and pLUG for life science research. Its molecular diagnostics division is engaged in the development and production of nucleic acid tester for infectious diseases. It also engages in the operation of veterinary antibiotic alternative business and new biopharmaceuticals development business. The Company distributes its products within domestic market and to overseas markets.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
0742 Veterinary services for animal specialties
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Co-Chief Executive Officer, Director Seong JunYoon 53
Co-Chief Executive Officer, Vice President, Director Gyeong WonYoon 51 1/1/2021
Vice President, Director Sang HyeonKang 54 1/1/2022
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 100 (As of 9/30/2016)
Outstanding Shares: 33,191,547 (As of 12/31/2023)
Shareholders: 22,701
Stock Exchange: KDQ
Fax Number: +82 317395353


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024